Initiate dosing patients in the PYX-201-102 combination trial
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 4 Feb 2025
- Due
- 31 Mar 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“is on track to initiate dosing patients in Q1 2025 as planned”
What we found
Evidence strength B What the grades mean
Company reported in its Q1 2025 update that it had initiated the PYX-201/pembrolizumab combination trial as planned, consistent with the Q1 2025 target.
-
B Pyxis Oncology Initiates New PYX-201 Combination Trial Announces trial actively recruiting, on track for Q1 2025 dosing
-
B Pyxis Oncology Granted FDA Fast Track Designation Confirms PYX-201-102 trial actively recruiting
-
C Pyxis Oncology Reports First Quarter 2025 Financial Results States company 'initiated' the combination study (past tense)
Checked 12 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.
- Second check: disagreesGemini (Google) re-read the evidence blind and read it as “no_evidence”.
- Tie-breakA stronger model read the evidence and both earlier answers, without knowing which was recorded, and agrees with the second check.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Pyxis Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2025-PYXS-000132 · Corrections policy